Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites

Trial ID or NCT#

NCT00326885

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of this study is to determine whether the investigational drug catumaxomab is a safe and effective treatment for recurrent symptomatic malignant ascites.

Official Title

A Single-Arm, Open-Label, Phase II Study to Assess the Safety and Efficacy of the Trifunctional Antibody Catumaxomab (Anti-EpCAM x Anti-CD3) Administered Intraperitoneally in Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites

Eligibility Criteria

Sexes Eligible for Study: FEMALE
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Jonathan S. Berek, MD, MMSc
Jonathan S. Berek, MD, MMSc
Gynecologic oncologist
Laurie Kraus Lacob Professor

Contact us to find out if this trial is right for you.

Contact

Colleen Fitzsimmons
6507243155

View on ClinicalTrials.gov